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INTRODUCTION
Bone formation on bioceramics, like calcium phosphate 
ceramics (CPCs), is well documented in animal models1–4 
and in humans.5 These ceramics showed to be appropriate 
carriers for bone morphogenetic proteins (BMPs)6,7 and 
cells.9,10 The main limitation of CPCs is to find the appro-
priate balance between degradability and mechanical sta-
bility.8,9 An ideal bone substitute should be degradable and 
should be replaced by newly formed bone in a short time10 
adapting to a dynamic processes as growth thought remodel-
ing.11 The degradation pattern of those ceramics is a critical 
issue especially in areas of highly aesthetic demands as the 
craniofacial region, because the grafted site should remain 
unaltered in shape after the ceramic is replaced by newly 
formed bone. Due to the need of long-lasting shape stability 
in craniofacial surgery, hydroxyapatite (HA)–based ceram-
ics have been traditionally used as nonresorptive materials 
for augmentation of the facial skeleton12 and cranial vault 
reconstruction.16,17 Beside the limited resorptive capacity of 
HA, bone formation has also been observed as limited.13,14 
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Background: The aim of the present study was to evaluate the degradation pattern 
of highly porous bioceramics as well as the bone formation in presence of bone 
morphogenetic protein 7 (BMP-7) in an ectopic site.
Methods: Novel calcium phosphate ceramic cylinders sintered at 1,300ºC with a total 
porosity of 92–94 vol%, 45 pores per inch, and sized 15 mm (Ø) × 5 mm were grafted 
on the musculus latissimus dorsi bilaterally in 10 Göttingen minipigs: group I (n = 5): 
hydroxyapatite (HA) versus biphasic calcium phosphate (BCP), a mixture of HA and 
tricalcium phosphate (TCP) in a ratio of 60/40 wt%; group II (n = 5): TCP versus 
BCP. A test side was supplied in situ with 250 μg BMP-7. Fluorochrome bone labeling 
and computed tomography were performed in vivo. Specimens were evaluated 14 
weeks after surgery by environmental scanning electron microscopy, fluorescence 
microscopy, tartrate-resistant acid phosphatase, and pentachrome staining.
Results: Bone formation was enhanced in the presence of BMP-7 in all ceramics (P = 0.001). 
Small spots of newly formed bone were observed in all implants in the absence of BMP-7. 
Degradation of HA and BCP was enhanced in the presence of BMP-7 (P = 0.001). In those 
ceramics, osteoclasts were observed. TCP ceramics were almost completely degraded inde-
pendently of the effect of BMP-7 after 14 weeks (P = 0.76), osteoclasts were not observed.
Conclusions: BMP-7 enhanced bone formation and degradation of HA and BCP ce-
ramics via osteoclast resorption. TCP degraded via dissolution. All ceramics were os-
teoinductive. Novel degradable HA and BCP ceramics in the presence of BMP-7 are 
promising bone substitutes in the growing individual. (Plast Reconstr Surg Glob Open 
2017;5:e1375; doi: 10.1097/GOX.0000000000001375; Published online 22 June 2017.)
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Long-term studies on HA cements for cranial reconstruction 
inform about a high rate of complications, particularly when 
using in proximity to the paranasal sinuses or in extended 
cranioplasties.16,20,21 Cranial full-thickness reconstruction re-
mains the major limitation for CPC.21 A highly degradable 
tricalcium phosphate (TCP) ceramic was proposed recently 
for cranial reconstruction. To maintain the implant shape a 
titan mesh was incorporated into the scaffold.5 A more ratio-
nal approach is to manage ceramic degradation by material 
composition. Biphasic calcium phosphate (BCP), a mixture 
of HA and TCP, combines the benefit of stability (HA) and 
degradability (TCP).10 The authors recently informed about 
enhanced degradability of BCP in the presence of BMP-7 
in a cranioplasty minipig model showing integrity of the 
grafted site after ceramic degradation occurred. Implants 
not loaded with BMP-7 collapsed, producing an irregular 
and depressed grafted site.15 There is limited knowledge 
about the mechanism of bioceramic degradation, whether 
through cellular digestion (osteoclast activity) or chemical 
dissolution.10 Understanding degradation mechanisms of 
ceramics plays a critical role in the design of specific im-
plants, considering individual mechanical and aesthetic 
demands.8 The ectopic animal implant model, also known 
as extra-skeletal or heterotopic model, is of value to evalu-
ate biomaterial degradation by dissolution (without cellular 
skeletal components) as well as for evaluation of bone for-
mation in the presence of BMPs16 or seeded cells.17
The hypotheses were (1) BCP implants will have a su-
perior degradation profile and improved bone formation 
compared with HA or TCP alone and (2) the addition 
of BMP-7 will significantly improve bone formation and 
bone degradation when compared with carrier alone.
MATERIALS AND METHODS
Ceramics used in this study were prepared from com-
mercially available HA and TCP powders (Merck, Darm-
stadt, Germany). For fabricating three-dimensional 
(3D) scaffolds, the polyurethane (PU) replica technique 
(Schwartzwalder-technique) was chosen. Therefore, com-
mercially available polyurethane-foams (pore size, 45 ppi) 
were coated with a calciumphosphate-slurry and sintered 
at 1,300°C for 1 hour. This procedure was repeated twice. 
The porous structure of the PU-foam was exactly repli-
cated, resulting in highly porous CaP ceramic scaffolds.18
Ten adult Göttingen minipigs aged 36 months in aver-
age and weighing 33–41 kg in average (Ellengard Göttingen 
Minipigs ApS, Dalmose, Denmark) were operated on. The 
animals were fed with 2 × 250 g standard soft diet (Altromin 
9023 Atronium International GmbH, Lange, Germany) 
and water ad libitum. The study was approved by the Dis-
trict of Oberpfalz, Bavaria (No. 54-2531.1-02/07) according 
to the animal protection law (TierSchG- § 8 Abs. 1) and the 
local Ethic Committee at the University of Regensburg. All 
experiments were performed at the Experimental Animal 
Facility at the University of Regensburg, Germany.
Experimental Procedure
The infrascapular region was cleaned with a povidone–
iodine solution and draped with sterile towels. Two paral-
lel incisions were marked and shaved below the scapular 
border laterally at a distance of 4 cm from each other, 
bilaterally. The skin incision was performed through the 
subcutaneous tissue until the latissimus dorsi muscle in 
the depth; gentle preparation of the skin flap above the 
muscle was performed. Highly porous CPC implants 
sized 15 × 5 mm developed at the Friedrich-Baur-Research-
Institute for Biomaterials at University of Bayreuth, Ger-
many, were implanted (Fig. 1). Ceramics used were HA, 
TCP, and a BCP in a weight ratio of 60/40% of HA/TCP. 
CPCs were sintered at 1,300º C.18 The CPCs have intercon-
necting macropores with a bimodal pore size distribution 
(360–440 μm and 900–1150 μm). The total porosity was 
92–94 vol%.2,18 Previous studies on the CPCs in vitro19 and 
in vivo in the mouse and minipig2,15 proved to be suitable 
for bone regeneration.
Two animal groups were evaluated (each n = 5); group 
I: HA versus BCP with and without BMP-7 (4 implants in 
each animal); group II: TCP versus BCP with or without 
BMP-7 (4 implants in each animal). In total, 40 implants 
were evaluated and compared for statistical purposes: HA 
(n = 5), TCP (n = 5), BCP (n = 10), HA + BMP-7 (n = 10), 
TCP + BMP-7 (n = 5), BCP + BMP-7 (n = 10). The test side 
was supplied in situ with 250 μg BMP-7 diluted in 20 mM 
acetate buffer with 5% mannitol (pH = 4.5) applied with 
a pipette (Eppendorf, Hamburg, Germany) providing full 
embedment of the implant (generous gift from Professor 
S. Vukicevic, Laboratory for Mineralized Tissues Center 
for Translational and Clinical Research, University of Za-
greb, School of Medicine and Genera, Krapinske Toplice, 
Croatia). The chosen dose seems to be appropriate, as no 
bone overgrowth behind the scaffold was observed when 
applying 250 μg BMP-7 in a cranioplasty model.15
In vivo computed tomography (CT) was performed 
at weeks 1, 10, and 14 after surgery in intravenous anes-
thesia as reported previously.15 Multiple in vivo CTs were 
performed to prove the presence of the ceramic after 
surgery and the progression of degradation before ter-
mination of the study at week 14. CT does not differenti-
ate between the ceramic and newly formed bone under 
the selected conditions (material composition).15 Histo-
Fig. 1. Ceramic implantation in the lateral subscapular region. Skin 
flap raised on the musculus latissimus dorsi. two parallel incisions 
were placed in both sides as implant recipient. Ceramics in the test 
side were supplied in situ with 250 μg Bmp-7.
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morphometry was performed by using environmental 
scanning electron microscope (ESEM).2,20 Core volume 
was evaluated according to Parfitt21 (core volume evalu-
ated area in mm2). 3D-CT reconstructions were per-
formed for visualization.
An in vivo polychrome sequential labeling of miner-
alizing tissues was performed as previously described.22 
Intraperitoneal injection of fluorochrome started 1 week 
after the surgical procedure and continued sequentially in 
weeks 6, 8, and 12 after surgery as follows: xylenol orange, 
calcein green, alizarin complexone, and doxycycline as re-
ported previously.15,23
Animals were killed 14 weeks after surgery by an intravi-
tal and intracardial perfusion of a saline and a Sörensen’s 
fixation solution24; a lateral thoracotomy was preferred.15
Histology
Each sample was harvested en bloc and sectioned in 
the middle after performing an x-ray. The surrounding 
soft tissues were preserved. One half of the specimens were 
prepared for methyl methacrylate (MMA) embedment ac-
cording to Donath,23,25,26 and the other half were prepared 
for paraffin embedment. Histomorphometry of newly 
formed bone and ceramic degradation was evaluated on 
en bloc MMA specimens analyzed by ESEM as previously 
described.2,15 The following parameters were evaluated21 by 
using an imaging software analySIS Pro3.2 (Soft Imaging 
Systems GmbH, Muenster, Germany): area of newly min-
eralized bone and area of ceramic (ratio evaluated in per-
centage). Subsequently, the MMA blocks were cut, ground, 
and polished into sections with a thickness of 90 μm. Those 
sections were evaluated for fluorescence labeling of newly 
formed bone.26
Paraffin-embedded specimens were treated with tar-
trate-resistant acid phosphatase (TRAP) for osteoclast 
identification. Movat’s pentachrome staining was per-
formed to visualize newly formed bone by self-induction 
(in the absence of BMP-7).27
Statistical Analysis
The statistical analysis was done with Stata 10.1 SE for 
Windows (StataCorp., Inc. College Station, Tex.) and Sig-
maPlot 11 for Windows (SYSTST Inc., Chicago, Ill.). Graphs 
were created with SigmaPlot 11. Data were graphically 
tested for normality with Q–Q plots, followed by a formal 
analysis with the Shapiro-Wilk test. Continuous, normally 
distributed data from more than 2 groups were compared 
with analysis of variance followed by pairwise comparison 
(Holm-Sidak). Comparison of 2 groups was done by Stu-
dent’s t test. Continuous, nonnormally distributed data 
from more than 2 groups were analyzed by means of the 
Kruskal-Wallis test, followed by a pairwise analysis with the 
Mann-Whitney test. Data are presented as mean value ± SD. 
A P value < 0.05 was considered as statistically significant.
RESULTS
Animals gained in average 5% weight during the ex-
perimental period of 14 weeks. The evolution was un-
eventful; no infections were observed.
Implant Volume on In-Vivo CT
Baseline in vivo CT data were acquired at week 1 after 
surgery (day 7) for all 3 ceramics (HA, TCP, and BCP). CT 
showed a progressive volume reduction in all implants not 
loaded with BMP-7 at weeks 10 and 14. The extension of 
the volume reduction was less on HA implants. TCP was 
almost not detectable at weeks 10 and 14. BMP-7 expand-
ed the volume of all ceramics (HA and BCP, P = <0.01; 
TCP, P = <0.4), showing a volume reduction at week 14 
(Fig. 2). Newly formed bone was not distinguished from 
the ceramic on CT.
ESEM with Correlation to TRAP and Movat’s Staining
Bone formation and ceramic degradation were eval-
uated by ESEM (Fig. 3). Bone formation was equally 
enhanced in the presence of BMP-7 in all evaluated ce-
ramics (HA, TCP, or BCP; P = 0.001; Fig. 3A; Fig. 4). 
Small spots of newly formed bone were observed in the 
absence of BMP-7 in all ceramics (Fig. 3B). The histo-
morphometry showed less bone formation in the almost 
collapsed TCP (P = 0.01; Fig. 3D; Fig. 4). Ceramic deg-
radation was enhanced in the presence of BMP-7 in the 
HA and in the BCP groups (P = 0.001; Fig. 3A; Fig. 5). 
In those ceramics, osteoclasts were observed via TRAP 
staining (Fig. 6). BMP-7 did not show a significant statis-
tical effect on TCP degradation after 14 weeks (P = 0.74; 
Fig. 5); osteoclasts were not observed via TRAP staining 
(Fig. 6). TCP without BMP-7 was almost completely de-
graded at the termination of the study; no osteoclasts 
were observed. Bone formation without BMP-7 was con-
firmed in all 3 ceramics in the pentachrome staining ac-
cording to Movat, showing dispersed immature primary 
bundle bone in front of the muscle; in the presence of 
Fig. 2. implant volume assessed in vivo by Ct at weeks 1, 10, and 
14. Ceramics not loaded with Bmp-7 drastically lost volume at week 
10; some volume recovered as observed at week 14 is explained by 
late bone formation, evident in fluorochrome labeling at week 10 
(see also Fig. 7). Bmp-7–stimulated ceramics showed a statistically 
significant volume increment. Volume reduction under Bmp-7 was 
observed from week 10 to week 14, explained by enhanced ceramic 
degradation evident in the ESEm (see Fig. 3; Student’s t test after 
testing for normality [tCp ceramics] or mann-Whitney test for non-
normally distributed data [Ha and BCp ceramics]).
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Fig. 3. ESEm images of explanted grafted CpC (total core) from the dorsal area. Small rectangle demarks the area of magnification. Colored 
areas show newly formed bone in blue and ceramic in red: newly formed bone is observed on and inside Ha ceramic in the presence of 
Bmp-7. Ha ceramic volume decreases in the presence of Bmp-7 (a). Small spots of newly formed bone (blue areas), marked with a white 
arrow, are observed on Ha ceramic without Bmp-7, confirming the self-osteoinductive property of this material (B). tCp ceramic in the 
presence of Bmp-7 has almost disappeared while bone formation was enhanced (C). tCp ceramic without Bmp-7 is almost completely 
degraded; small spots of newly formed bone (blue areas), marked with a white arrow, are observed (D). BCp ceramics in the presence of 
Bmp are fully integrated in newly formed bone (E), Bmp-7 enhanced ceramic degradation (see also Fig. 6). BpC ceramic without Bmp-7 
is partially collapsed. Small spots of newly formed bone (blue areas, white arrow) confirm again the self-osteoinductive property of this 
material (F), (undecalcified in mma embedded specimens en bloc analyzed, composite images, scale bar: 3.5 mm).
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BMP-7, extensive lamellar bone was observed in the to-
tal core (images not shown).
Temporal Bone Formation Assessed by Intravital 
Fluorochrome Labeling
Fluorochrome staining revealed bone formation in 
the presence of BMP-7 at week 1 {xylenol orange = yellow; 
Fig. 7A, C, E [HA (A), TCP (C), BCP (E)]}. Fluorochrome 
histomorphometry showed a higher bone formation at 
week 6 (calcein green = green) compared with weeks 8 
and 12 (P = 0.005). No significant difference was observed 
in terms of bone formation in the presence of BMP-7 in 
all ceramics at week 6 (P = 0.32), week 8 (P = 0.70), and 
week 12 (P = 0.18). Bone formation without BMP-7 was 
confirmed through fluorochrome labeling at week 8, de-
tected by small red spots (alizarin complexone = red) in a 
partially collapsed scaffold (Fig. 7).
DISCUSSION
In the present study, the degradability of CPC could be 
demonstrated by a cellular (osteoclast) and by chemical 
dissolution in an ectopic site. HA and BCP were signifi-
cantly degraded in the presence of BMP-7 (P = 0.001). In 
those ceramics, osteoclasts were observed on TRAP stain-
ing. Osteoclasts were also observed on BCP without BMP-
7, but in this case, no statistically significant enhanced 
degradability was observed.
Degradation of CPC in the Experimental Setting
In previous in vitro studies on the present CPCs, osteo-
clastogenesis was evaluated by using RAW 264.7 murine 
monocytes stimulated with receptor activator of NF-κB 
ligand and macrophage colony-stimulating factor for 21 
days. Those cells differentiated in 14 days in osteoclast-
like cells. Resorptive lacunae on BCP were measured 
with a depth of 10–12 μg and diameters of 30–40 μm on 
ESEM. Osteoclast lacunae were also observed on HA but 
not in ß-TCP.28 In the present study, osteoclasts were not 
observed on TCP; at termination of the study at week 14, 
almost no ceramic was observed and the effect of BMP-7 
did not change the degradability of this material. Control 
TCP (without BMP-7) was almost completely degraded, 
only small spots of newly formed bone (osteoinductive 
bone) were observed. The degradability of TCP is attrib-
uted mainly to chemical dissolution.10 Furthermore, the 
chemical dissolution of TCP increases the Ca2+ ion con-
centration, which inhibits osteoblast formation in vitro.29 
Yamada et al. showed enhanced osteoclastogenesis in vi-
tro on BCP (in a ratio of HA:ß-TCP of 100:0 and 80:20). 
Lacunae pits were not observed in TCP.30 Mayr et al. pro-
posed an HA:ß-TCP ratio of 80:20 to 60:40 based on a 
osteoclastogenesis in vitro model.31 In the present study 
on BCP, an HA/TCP ratio of 60:40 was chosen. It is well 
known that osteoclastogenesis is influenced by different 
material properties, such as chemical composition and 
crystallinity of the ceramic, topography, and micro- as well 
as macroporosity of the scaffolds. All these aspects influ-
ence cell adhesion and thus osteoclastogenesis.10 Because 
the geometry, composition, and sintering process of CPC 
directly influence bone formation and also biodegrad-
ability,32 each particular biomaterial should be character-
ized, defining the biodegradable properties (dissolution 
versus resorption) for a specific anatomical area.29
Whether the degradability is an important feature of a 
scaffold, replacement by newly formed bone is also a criti-
cal issue because the grafted site should remain unaltered in 
shape. Recently, the authors informed about enhanced deg-
radation of cranial implants in the presence of BMP-7, where-
as the grafted site remained unchanged in shape. Ceramics 
nonloaded with BMP-7 showed a delayed bone formation in 
a collapsed scaffold changing the shape of the grafted site.15
Fig. 4. area of newly mineralized bone assessed by ESEm. Enhanced 
bone formation was statistically observed in all ceramics (Ha, tCp, 
and BCp) in the presence of Bmp-7 (P = 0.001), no statistical differ-
ences were observed between the ceramics (normality test Shapiro-
Wilk, failed P < 0.05).
Fig. 5. area of calcium phosphate ceramics assessed by ESEm. Bmp-
7 enhanced ceramic degradation on Ha and BCp (P = 0.001). Osteo-
clasts were observed in those ceramics (see Fig. 8). Degradability 
of tCp was not affected by Bmp-7 (P = 0.76). tCp was degraded via 
chemical dissolution as no cellular component (osteoclasts) was ob-
served in the trap staining (see Fig. 8;, normality test Shapiro-Wilk, 
failed P < 0.05).
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Effects of BMP on Calcium Phosphate Ceramics and 
Degradation
The effects of BMP on ceramics are widely document-
ed for bone formation, but the effects on ceramic degra-
dation are scarce. To the best of our knowledge, this study 
is the first one evaluating biodegradability of CPC, pro-
viding evidence of osteoclast activity or chemical dissolu-
tion in the presence of BMP-7 in vivo. We also previously 
observed an enhanced ceramic degradation in the pres-
ence of BMP-7 in an ectopic mouse model.2 Osteoclasts 
have been observed in the present ceramic for the first 
time by TRAP staining in vivo. Ripamonti et al.33 evalu-
ated sintered HA ceramics implanted ectopically (rectus 
abdominis muscle) in the adult primate in the presence 
of 5, 25, and 45 μg BMP-7. After 30 and 90 days, bone 
formation was enhanced, but the ceramic did not show a 
statistically significant degradation. Draenert et al.34 stated 
an enhanced bone remodeling and ß-TCP “resorption” 
when adding BMP-7, but osteoclasts were not evaluated. 
The mechanism of degradation of CPC in vivo is often 
not considered; the term “resorption” is generally used 
for degradation whether or not osteoclastic resorption or 
chemical dissolution has been observed. Abe et al.35 evalu-
ated the effect of BMP-2/4 on osteoblasts and osteoclasts 
in vitro: Noggin, a BMP antagonist, blocked osteoblastic 
as well as osteoclastic differentiation, thus explaining the 
effect of BMP on bone remodeling. Thus, ceramic degra-
dation and ceramic replacement by newly formed bone 
should resemble bone remodeling as an orchestrated pro-
cess of bone formation and bone/ceramic resorption; this 
process is supported by BMP. In the present study, HA as 
well as BCP combined with BMP-7 showed no statistical 
difference in terms of bone formation and ceramic deg-
radation. The benefit of BCP combined with BMP-7 lies 
in the adjustable degradability of the implant by changing 
the HA/TCP ratio matching the implant to the mechani-
cal demands in a particular anatomical area while BMP-
7 strengthens the highly degradable TCP component 
through bone formation.
Bone Formation on Calcium Phosphate Ceramics: 
Osteoinduction by BMP and Self-Osteoinduction
In the present study, BMP-7 enhanced bone formation 
in all ceramics equally. This result underlines that the limi-
tation of BMP is the scaffold and the critical issue is the 
scaffold degradability. The temporal apposition of bone 
assessed by in vivo fluorochrome labeling disclosed early 
bone formation as a critical issue for further bone apposi-
tion before the ceramic collapse, as also observed when 
the ceramic is implanted at a skeletal site.15 Bone forma-
tion was observed at week 1 in BMP-7 stimulated implants, 
supporting further bone apposition. Nonstimulated BMP-
Fig. 6. trap staining on CpC explanted from the dorsal area. Osteoclasts are identified on Ha and BCp 
ceramics in the presence of Bmp-7 (a and B) and on BCp ceramics in the absence of Bmp-7 (C; black ar-
row). no osteoclasts were seen on tCp whether or not stimulated with Bmp-7 (D) (magnification 10x).
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Fig. 7. Fluorochrome labeling of explanted grafted CpC from the dorsal area (total core), (xylenol orange/orange yellow marker at week 
1; calcein green/green marker at week 6; alizarin complexone/red marker at week 8; doxycycline/ brown marker at week 12). rectangle 
marks the area of magnification. Ceramics stimulated with Bmp-7 (a, C, E) show newly formed bone starting at week 1 (yellow marker), 
successive bone formation (weeks 6, 8, and 12) takes place throughout the implant site. new bone formation in the absence of Bmp-7 is 
detected as small red spots (week 8) on Ha (B), tCp (D), and BCp (F), confirming osteoinductive property of the evaluated ceramics (unde-
calcified in mma-embedded specimens en block analyzed, composite images, scale bar 3.5 mm).
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7 implants collapsed. TCP needs a strong BMP stimulus, 
before the ceramic disappears, as observed in the control 
site (no BMP), which was evident at week 10 on in vivo CT. 
All studied ceramics showed osteoinductive properties. 
This effect is not only influenced by the material composi-
tion36 but also by the geometry.19,37,38 Deproteinized bovine 
bone (Bio-Oss) does not display osteoinductive properties 
in an ectopic site, even if the scaffold architecture is similar 
to human bone.26 Ceramic osteoinduction (without BMP) 
was detected in the present study as small spots of newly 
formed bone in ESEM and fluorochrome labeling starting 
at week 8. This effect was confirmed in the pentachrome 
staining directly in front of the muscle, where the vascu-
larization is higher. This observation supports the critical 
role of angiogenesis in bone formation and also the ecto-
pic site as an ideal implant site for scaffold prefabrication 
in a clinical setting. Nevertheless, the scarce amount of 
newly formed bone in absence of BMP-7 was not relevant 
for a clinical purpose under the selected conditions.
The osteoinductive properties of BMPs, described for 
the first time by Urist39 in 1965, have not been observed in 
the presence of any other cytokine signal or material; BMP 
remains the most effective therapeutic tool in bone regen-
eration.32 Attempts for enhancing effect of BMP with an 
appropriate functionalized osteoinductive scaffold40 aims 
to reduce dose and cost. Furthermore, dose should be 
matched to the defect size and localization.41
Clinical Relevance: Perspective
According to the mentioned characteristics of CPC 
under the influence of BMP, the following clinical ben-
efits can be mentioned: CPC is degradable via resorption 
(HA-based CPC) and dissolution (TCP). This effect is en-
hanced by BMP. CPC under BMP undertakes a remodel-
ing process based on bone formation and bone/ceramic 
resorption. This remodeling process is a prerequisite to 
fit those implants to architectural changes in the growing 
infant. CPC is unlimited in source and can be tailored as a 
3D implant with a defined inter- and intraconnective pore 
system and tailored as a patient-specific implant via com-
puter-aided design. Implant straightness can be achieved 
changing the HA:TCP ratio, being higher augmenting 
the HA content. In those implants, a higher dose of BMP 
could be required to enhance degradation and remod-
eling. All mentioned aspects indicate that the future in 
bone regeneration lies in the development of patient-spe-
cific implants, not only in terms of surface shape but also 
in terms of internal architecture and composition. CPC 
seams to meet those requirements.
CONCLUSIONS
The evaluated CPCs are resorbable (HA), dissolv-
able (TCP), and osteoinductive. BMP-7 enhanced HA 
and BCP degradation via osteoclastic resorption and en-
hanced bone formation, integrating the ceramic in the 
bone remodeling process. In terms of bone formation and 
ceramic degradation, BCP was not superior to HA in the 
presence of BMP-7 as hypothesized. The benefit of BCP 
combined with BMP-7 lays in the adjustable degradabil-
ity of the implant by changing the HA/TCP ratio, while 
BMP-7 strengthens the highly degradable TCP compo-
nent through bone formation. Those features make this 
biomaterial promising for the treatment of bone defects, 
especially in the growing infant, where implant remodel-
ing is of major importance.
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